{"id":"cytoflavin-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cytoflavin contains succinic acid and flavin mononucleotide (riboflavin derivative), which work synergistically to improve mitochondrial function and ATP production. It acts as an antioxidant and metabolic activator, helping restore cellular energy metabolism in conditions characterized by hypoxia or metabolic dysfunction.","oneSentence":"Cytoflavin is a combination drug that enhances cellular energy metabolism and reduces oxidative stress through its active components.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:18.636Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Traumatic brain injury"},{"name":"Hypoxic-ischemic encephalopathy"},{"name":"Acute cerebrovascular disorders"}]},"trialDetails":[{"nctId":"NCT05935787","phase":"PHASE3","title":"Cytoflavin in the Complex Rehabilitation of Stroke Patients","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2023-06-09","conditions":"Stroke","enrollment":240},{"nctId":"NCT06514976","phase":"","title":"Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy","status":"RECRUITING","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2024-03-01","conditions":"Stroke, Acute, Stroke, Ischemic","enrollment":562},{"nctId":"NCT04631484","phase":"PHASE3","title":"International Trial of Efficacy of Cytoflavin in Head Trauma","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2020-11-22","conditions":"Head Trauma,Closed","enrollment":166},{"nctId":"NCT06735898","phase":"","title":"Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome","status":"RECRUITING","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2024-03-01","conditions":"Ischemic Stroke","enrollment":90},{"nctId":"NCT04194229","phase":"","title":"Cytoflavin in the Rehabilitation of Post-intensive Care Syndrome in Stroke Survivors","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2016-11-11","conditions":"Ischemic Stroke, Post Intensive Care Unit Syndrome","enrollment":60},{"nctId":"NCT05297851","phase":"","title":"Cytoflavin in Combination With Reperfusion in Stroke Patients","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2022-04-10","conditions":"Acute Stroke","enrollment":200},{"nctId":"NCT03849664","phase":"PHASE3","title":"Efficacy and Safety of Cytoflavin® Used in Elderly Patients for the Prevention of Cognitive Decline After Major Surgery","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2017-06-02","conditions":"Cognitive Dysfunction","enrollment":200},{"nctId":"NCT04649203","phase":"PHASE3","title":"Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2020-11-25","conditions":"Diabetic Neuropathies","enrollment":216}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inosine + Nicotinamide + Riboflavin + Succinic Acid solution"],"phase":"phase_3","status":"active","brandName":"Cytoflavin® solution","genericName":"Cytoflavin® solution","companyName":"POLYSAN Scientific & Technological Pharmaceutical Company","companyId":"polysan-scientific-technological-pharmaceutical-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cytoflavin is a combination drug that enhances cellular energy metabolism and reduces oxidative stress through its active components. Used for Acute ischemic stroke, Traumatic brain injury, Hypoxic-ischemic encephalopathy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}